Eprosartan was successfully developed by SK&F in 1997 and launched in Germany in 1998 under the brand name Teeten. The overseas price for 400mg x 100 tablets was $94. The compound patent EP0403159 was applied for in 1989, and the imported product is about to be filed for production domestically and obtain approval.
I. Introduction to Eprosartan
According to Yayaoyou.com, Eprosartan is an angiotensin II receptor blocker and belongs to the latest generation of antihypertensive drugs. Clinical studies have shown that this drug is effective in reducing both systolic and diastolic blood pressure in patients with mild, moderate, and severe hypertension, and it has good safety and tolerability. As a highly efficient and selective subtype 1 (AT1) angiotensin receptor antagonist, Eprosartan methanesulfonate reduces blood pressure by blocking the angiotensin II receptor. It is rapidly absorbed orally, with a bioavailability of 13%, and plasma protein binding rate of 98%. In patients with hepatic or renal insufficiency or after taking the drug on a full stomach, the peak plasma concentration and AUC can increase by about 50%, and in elderly patients, it can increase 2-3 times. Common side effects of Eprosartan include upper respiratory tract infections, rhinitis, pharyngitis, cough, fatigue, abdominal pain, and arthralgia. For most hypertensive patients, regardless of age, race, gender, and severity of hypertension, this drug is effective. Recent research shows that Eprosartan can prevent recurrent strokes. Bioail company recently announced that angiotensin II receptor blockers (ARBs) not only lower blood pressure in hypertensive patients with a history of stroke but also prevent cardiovascular and cerebrovascular diseases.
II. Production and usage situation of this variety at home and abroad
Eprosartan was successfully developed by SK&F in 1997 and launched in Germany in 1998 under the brand name Teeten, followed by its launch in the United States in 1999. However, it has not been included in pharmacopoeias, and China has not imported it either. Currently, Eprosartan is not yet available for sale domestically. Bioail company has the sales rights for this product and its combination formulations in the US market. The market value of this product and its combination formulations is approximately $4 billion. In the United States, Eprosartan is one of the fastest-growing classes of antihypertensive drugs in terms of market sales. According to Datamonitor's forecast, Eprosartan's revenue in 2010 could reach $600 million.